A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.

Chan, Stephen L; Yeo, Winnie; Mo, Frankie; Chan, Anthony W H; Koh, Jane; Li, Leung; Hui, Edwin P; Chong, Charing C N; Lai, Paul B S; Mok, Tony S K; Yu, Simon C H

Chan, Stephen L; Yeo, Winnie; Mo, Frankie; Chan, Anthony W H; Koh, Jane; Li, Leung; Hui, Edwin P; Chong, Charing C N; Lai, Paul B S; Mok, Tony S K; Yu, Simon C H.

Afiliação

Chan SL; State Key Laboratory of Oncology in South China, Hong Kong.
Yeo W; Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Mo F; Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong.
Chan AWH; State Key Laboratory of Oncology in South China, Hong Kong.
Koh J; Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Li L; State Key Laboratory of Oncology in South China, Hong Kong.
Hui EP; Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Chong CCN; State Key Laboratory of Oncology in South China, Hong Kong.
Lai PBS; Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong.
Mok TSK; Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Yu SCH; Sir YK Pao Center for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.

Cancer ; 123(20): 3977-3985, 2017 Oct 15.

Article em En | MEDLINE | ID: mdl-28640364

Assuntos

Antineoplásicos/administração & dosagem; Carcinoma Hepatocelular/terapia; Quimioembolização Terapêutica/métodos; Imidazóis/uso terapêutico; Indazóis/uso terapêutico; Neoplasias Hepáticas/terapia; Inibidores de Proteínas Quinases/uso terapêutico; Idoso; Alanina Transaminase/metabolismo; Fosfatase Alcalina/metabolismo; Axitinibe; Bilirrubina/metabolismo; Carcinoma Hepatocelular/metabolismo; Carcinoma Hepatocelular/patologia; Progressão da Doença; Intervalo Livre de Doença; Feminino; Humanos; Coeficiente Internacional Normatizado; Neoplasias Hepáticas/metabolismo; Neoplasias Hepáticas/patologia; Masculino; Pessoa de Meia-Idade; Análise Multivariada; Modelos de Riscos Proporcionais; Receptores de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores; Taxa de Sobrevida; Resultado do Tratamento; Carga Tumoral

Palavras-chave

cancer; drug development; hypertension; interventional radiology; liver

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimioembolização Terapêutica / Carcinoma Hepatocelular / Inibidores de Proteínas Quinases / Imidazóis / Indazóis / Neoplasias Hepáticas / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Hong Kong

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google